Carotuximab

DRUG2 trials

Sponsors

Karen Reckamp, MD, MS, Edwin Posadas, MD

Conditions

Castration-resistant Prostate CancerLung CancerNon Small Cell Lung Cancer

Phase 1

Study of Osimertinib With Carotuximab in Advanced, EGFR-mutated Non-Small Cell Lung Cancer

RecruitingNCT05401110

Karen Reckamp, MD, MSLung Cancer, Non Small Cell Lung Cancer

Start: 2023-09-15End: 2029-01-01Target: 60Updated: 2026-08-06

Phase 2

Study of Apalutamide With Carotuximab in Metastatic, Castration-Resistant Prostate Cancer

RecruitingNCT05534646

Edwin Posadas, MDCastration-resistant Prostate Cancer

Start: 2023-12-27End: 2027-01-01Target: 100Updated: 2026-02-02

Related Papers

Effect of carotuximab (ENV105)-mediated CD105 blockade on osimertinib sensitivity in EGFR-mutant non-small cell lung cancer persister cells.

Journal of Clinical Oncology2025-05-28

A randomized phase II study of apalutamide with or without carotuximab (ant-CD105) in metastatic, castration-resistant prostate cancer.

Journal of Clinical Oncology2023-06-014 citations